Taking into account the foregoing, it seems reasonable to conclude that Gal-3 can be used as a prognostic marker for heart failure and is also well indicated in diabetic myocardium and that inhibition of Gal-3 to reduce inflammation and fibrosis is a potential therapeutic approach to prevent heart disease. This evidence concerns the gene LGALS3 and heart failure.